Aimmune Therapeutics to Participate in Two Upcoming Medical Meetings
The European Academy of Allergy and Clinical Immunology’s 4th
Food Allergy and Anaphylaxis Meeting (FAAM),
October 13-15, 2016, in Rome
The 2016 Annual Scientific Meeting of the
American College of Asthma, Allergy & Immunology(ACAAI), November 10-14, 2016, in San Francisco
Details for Aimmune Presentations at FAAM,
#PP145: “The Stability of Peanut Allergens in AR101, an Oral
Immunotherapeutic for the Treatment of Peanut Allergy, in Two
Representative Food Matrices” (Presenting author: R. Simon) on
Saturday, October 15, 11:30 AM– 1:00 PM, in Poster Session 4 (Food Allergens) in the Poster Area (La Piazzetta B & C).
Aimmune will host an Industry Satellite Symposium titled “Peanut
Allergy Oral Immunotherapy: Exploring the Needs of Peanut-Allergic
Patients and Their Families” on
George Du Toit, M.B., B.Ch., Guy’s and St Thomas’ Hospital, London, and Evelina Children’s Hospital, London, Moderator
Audrey Dunn Galvin, Ph.D., University College Cork, Ireland, “Defining the Unmet Needs of Peanut-Allergic Patients and Their Families”
Andrea Vereda, M.D., Ph.D., Aimmune Therapeutics, “Targeting the Growing, Unmet Need for Peanut Allergy Treatment: Aimmune’s Clinical Development Approach”
Details for Aimmune Presentations at ACAAI,
#O055: “Immunologic Effects of AR101 During Characterized Oral
Desensitization Immunotherapy (CODIT) for Peanut Allergy”
(Presenting author: E. Kim) on
Monday, November 14.
#O056 “Baseline Peanut-Specific IgE Potentially Predicts Up-Dose
Completion and Treatment Response with AR101 in CODIT” (Presenting
Wang) on Monday, November 14.
Aimmune will host a
Additional details will be available closer to the time of the meeting.